Table 1 –

Summary of experimental observations for respiratory virus release inhibited by BST-2

Virus	Family	Experimental Observations
Influenza A	Orthomyxovirus	Observations have been strain-specific. Some report BST-2 does not inhibit IAV release.[17, 19, 31] Others report BST-2 inhibits IAV VLP release; dependent on neuraminidase sequence.[18, 20, 21, 32, 33] Others report BST-2 inhibits infectious IAV and IAV VLPs, enhanced by loss of IAV M2.[34] NS1, which broadly targets ISG expression at the RNA level, may partially inhibit BST-2 by lowering expression. [31, 32]
PIV2	Paramyxovirus	BST-2 inhibits PIV2 release.[35]
Sendai (SeV)	Paramyxovirus	BST2 inhibits SeV release from PM.[38]
SARS CoV	Coronavirus	BST-2 inhibits SARS release from PM; more strongly inhibits SARS-ORF7abΔ release from PM.[37]
Human CoV 229E (hCoV-229E)	Coronavirus	BST-2 inhibits hCoV-229E release from the PM.[36]
Porcine reproductive and respiratory syndrome virus (pRRSV)	Arterivirus	pRRSV E protein interacts with BST-2 by yeast two-hybrid and mislocalizes it from surface; BST-2 doesn’t inhibit pRRSV.[39]

Key: SARS = severe acute respiratory syndrome; CoV = coronavirus; PIV = parainfluenza virus; PM = plasma membrane; SARS-ORF7abΔ = SARS with ORF7a and ORF7b deleted.